Sharing is caring!

Oxford and AstraZeneca’s COVID-19 vaccine candidate shows 90% efficacy in clinical trials. 

The late-stage human trials for the COVID-19 vaccine candidate developed by Oxford University and AstraZeneca showed that the vaccine could be up to 90% effective.

The preliminary result showed that a lower dose appeared to be more effective. The volunteers were first given half a dose of the vaccine, followed by a full dose at least one month apart, efficacy was 90%. Whereas, when volunteers were given two full doses at least one month apart, efficacy was at 62%.

The combined analysis from both dosing regimens involving more than 11,000 volunteers resulted in an average efficacy of 70%.

Both companies said that more data will continue to accumulate and additional analysis will be conducted to improve the efficiency reading and establish the duration of immunization.

(Source: The Straits Times, 2020)

Pfizer COVID-19 vaccine could get UK approval this week: Report

Pfizer and BioNTech’s COVID-19 vaccine candidate is expected to be approved by Britain this week. 

Through government sources, British regulators were said to commence a formal appraisal of the vaccine, made by Pfizer and BioNTech, and that the National Health Service had been told to be ready to administer it by December 1st, 2020. 

The US Food and Drug Administration (FDA) said last Friday (November 20, 2020) that it would meet on December 10, 2020 to discuss the authorization of the vaccine. While the UK Department of Health did not comment on when the first vaccinations would be administered. 

(Source: Channel News Asia, 2020)

European Union snags 160 million doses of Moderna’s mRNA-based COVID-19 vaccine. 

Moderna and the European Union recently finalized a deal to supply 160 million doses of the mRNA-based COVID-19 shot developed by Moderna. This is estimated to immunize 80 million patients based on Moderna’s two-dose regimen.

The newest supply agreement comes a week after the European Union accepted Moderna’s mRNA-1273 vaccine, for rolling review based on interim results from a phase 3 study showing 95% efficacy. 

Moderna also plans to submit the vaccine for the US Food and Drug Administration’s (FDA) emergency use authorization within a few weeks. 

(Source: Fierce Pharma, 2020)